SCHEMBL16661200

SCHEMBL16661200

CSc1n[nH]c(-c2ncc(Br)cc2Cl)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DCUN1D1 Q96GG9 9/20 0.42
▸ KDM4E B2RXH2 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ ALPL P05186 1/20 0.37
▸ PLAU P00749 1/20 0.35
▸ LMNA P02545 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ PPARG P37231 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ DYRK1A Q13627 2/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16661369 0.83 DCUN1D1 (0.42) DCUN1D1KDM4ENPC1POLBRAB9A
SCHEMBL16661263 0.75 DCUN1D1 (0.48) DCUN1D1KDM4ENPC1POLBRAB9A
SCHEMBL16661030 0.75 DCUN1D1 (0.49) DCUN1D1KDM4ENPC1POLBRAB9A
SCHEMBL16661001 0.72 DCUN1D1 (0.49) DCUN1D1KDM4ENPC1POLBRAB9A
SCHEMBL16661253 0.71 KDM4E (0.41) KDM4EPLAULMNASMN1; SMN2DYRK1A
SCHEMBL16661193 0.67 DCUN1D1 (0.69) DCUN1D1KDM4ENPC1POLBRAB9A
SCHEMBL20064678 0.67 KMT2A (0.47) KDM4ENPC1RAB9APLAULMNA
SCHEMBL16661201 0.66 DCUN1D1 (0.57) DCUN1D1KDM4ENPC1POLBRAB9A
SCHEMBL7843693 0.66 PLAU (0.42) KDM4EPLAULMNASMN1; SMN2DYRK1A
SCHEMBL8158453 0.64 DCUN1D1 (0.74) DCUN1D1KDM4ENPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10308636-B2 Aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-04 — — US disclosed
EP-2862856-B1 IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2018-08-01 — — EP disclosed
US-20170050950-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-02-23 — — US disclosed
US-20170050950-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-02-23 — — US disclosed
US-9546155-B2 Aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-17 — — US disclosed
US-9546155-B2 Aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-17 — — US disclosed
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-06-11 — — US disclosed
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-06-11 — — US disclosed
EP-2862856-A1 AROMATIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2015-04-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND GPR119, NR0B1, BET1 DCUN1D1 276/4885KDM4E 1080/4885NPC1 796/4885
US-10308636-B2 Aromatic heterocyclic compound GPR119, NR0B1, BET1 DCUN1D1 276/4885KDM4E 1080/4885NPC1 796/4885
US-20170050950-A1 AROMATIC HETEROCYCLIC COMPOUND GPR119, NR0B1, BET1 DCUN1D1 276/4885KDM4E 1080/4885NPC1 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback